Verve Therapeutics priced its initial public offering of common stock at $19.00 per share. The upsized public debut successfully raised approximately $266.7 million in gross proceeds before factoring in underwriting discounts, commissions, and standard offering expenses. As a pioneering biotechnology enterprise focused on developing single-course gene-editing medicines for cardiovascular diseases, the company's market launch drew substantial institutional and retail investor interest, making it one of the notable biotech public offerings of that year.
On the Australian Securities Exchange, the ticker code ACF officially represents Acrow Limited, a prominent industrial services and construction engineering enterprise. The company specializes in providing high-performance formwork, scaffolding, shoring systems, and industrial access engineering solutions to major civil infrastructure works, commercial high-rises, and industrial projects across Australia. Investors utilize this specific exchange code to track stock price movements, execute buy or sell orders, and review corporate disclosures.